Clinical Implication of VMAT for Chemoradiation in CePh-Type Cervical Esophageal Cancer and Hypopharyngeal Cancer Extending to the Cervical Esophagus

Clinical Implication of VMAT for Chemoradiation in CePh-Type Cervical Esophageal Cancer and Hypopharyngeal Cancer Extending to the Cervical Esophagus - Cohort study of VMAT for CePh-Type Cervical Esophageal Cancer and Hypopharyngeal Cancer Extending to the Cervical Esophagus

Status

Recruiting

Phases

Phase 1

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000026403

Enrollment

Registered

2017-09-30

Start date

2011-07-02

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

CePh-type cervical esophageal carcinoma and hypopharyngeal cancer with esophageal invasion

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients of CePh-type esophageal cancer and hypopharyngeal cancer with esophageal invasion to be treated with definitive concurrent chemoradiation (CCRT), without any RT history in the head and neck and thorax. Before initial intent dose is administered, if patients was changed from CCRT to induction CRT(RT dose is less than or = 50Gy ) followed by salvage surgery, they are selected by initial intent.

Exclusion criteria

Exclusion criteria: Patients diagnosed as M1 or M1lym, patients whose primary subsite of cervical esophageal cancer is CeUt with more than 1cm Ut invasion, patients whose primary subsite of hypopharyngeal cancer is pyriform sinus because of a slight difference of nodal area between defined the patients for this protocol.

Design outcomes

Primary

Measure	Time frame
Three year OSs are presented in following groups, respectively: 1.the cohort group; CePh-type cervical esophageal cancer, 2.the cohort group; hypopharyngeal cancer with esophageal invasion, 3.the control group; CePh-type cervical esophageal cancer, and 4.the control group; hypopharyngeal cancer with esophageal invasion	—

Secondary

Measure	Time frame
In the cohort group and the control group, 3-year recurrent free survival (RFS), occurrence rates of acute and late toxicities are presented, respectively ('Acute' means within 3 months after CCRT beginning). All toxicities are referred by CTCAE ver.4.0.	—

Countries

Japan

Contacts

Public ContactNobuo HONGO

Social care corporation Keiyukai sapporo Hospital Administrative office

nhongo@keiyukaisapporo.or.jp011-863-2101

Outcome results